Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 91

1.

FDG-PET on the trail of an unsuspected primary malignancy in the breast.

Dockery KF, Puri S, Qazi R, Davis D.

Clin Nucl Med. 2008 Mar;33(3):175-80. doi: 10.1097/RLU.0b013e318162ddee.

PMID:
18287839
2.

FDG PET, PET/CT, and breast cancer imaging.

Rosen EL, Eubank WB, Mankoff DA.

Radiographics. 2007 Oct;27 Suppl 1:S215-29. doi: 10.1148/rg.27si075517. Review.

PMID:
18180228
3.

A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer.

Kauhanen SP, Komar G, Seppänen MP, Dean KI, Minn HR, Kajander SA, Rinta-Kiikka I, Alanen K, Borra RJ, Puolakkainen PA, Nuutila P, Ovaska JT.

Ann Surg. 2009 Dec;250(6):957-63. doi: 10.1097/SLA.0b013e3181b2fafa.

PMID:
19687736
4.
5.

Early prediction of response to chemotherapy in metastatic breast cancer using sequential 18F-FDG PET.

Dose Schwarz J, Bader M, Jenicke L, Hemminger G, Jänicke F, Avril N.

J Nucl Med. 2005 Jul;46(7):1144-50.

6.

Intra-operative use of PET probe for localization of FDG avid lesions.

Molina MA, Goodwin WJ, Moffat FL, Serafini AN, Sfakianakis GN, Avisar E.

Cancer Imaging. 2009 Sep 29;9:59-62. doi: 10.1102/1470-7330.2009.0009.

7.

Intraductal papilloma of the breast: F-18 FDG PET demonstration.

Nguyen BD, Lidner TK.

Clin Nucl Med. 2005 Jul;30(7):481-2. No abstract available.

PMID:
15965323
8.

F-18 FDG positron emission tomography in non-Hodgkin lymphoma of the breast.

Kumar R, Xiu Y, Dhurairaj T, Yu JQ, Alavi A, Zhuang H.

Clin Nucl Med. 2005 Apr;30(4):246-8.

PMID:
15764881
9.

Evaluation of recurrent gastric malignancy with [F-18]-FDG positron emission tomography.

Jadvar H, Tatlidil R, Garcia AA, Conti PS.

Clin Radiol. 2003 Mar;58(3):215-21. Erratum in: Clin Radiol. 2003 Jul;58(7):570.

PMID:
12639527
10.
11.

Clinical staging of patients with early esophageal adenocarcinoma: does FDG-PET/CT have a role?

Cuellar SL, Carter BW, Macapinlac HA, Ajani JA, Komaki R, Welsh JW, Lee JH, Swisher SG, Correa AM, Erasmus JJ, Hofstetter WL.

J Thorac Oncol. 2014 Aug;9(8):1202-6. doi: 10.1097/JTO.0000000000000222.

12.
13.

Value of fluorodeoxyglucose positron emission tomography in women with breast cancer.

Landheer ML, Steffens MG, Klinkenbijl JH, Westenberg AH, Oyen WJ.

Br J Surg. 2005 Nov;92(11):1363-7.

PMID:
16187254
14.
15.

Clinicopathological and prognostic relevance of uptake level using 18F-fluorodeoxyglucose positron emission tomography/computed tomography fusion imaging (18F-FDG PET/CT) in primary breast cancer.

Ueda S, Tsuda H, Asakawa H, Shigekawa T, Fukatsu K, Kondo N, Yamamoto M, Hama Y, Tamura K, Ishida J, Abe Y, Mochizuki H.

Jpn J Clin Oncol. 2008 Apr;38(4):250-8. doi: 10.1093/jjco/hyn019.

PMID:
18407934
16.

Evaluation of fluorodeoxyglucose positron emission tomography in the detection of axillary lymph node metastases in patients with early-stage breast cancer.

Barranger E, Grahek D, Antoine M, Montravers F, Talbot JN, Uzan S.

Ann Surg Oncol. 2003 Jul;10(6):622-7.

PMID:
12839846
17.

Is there a role for positron emission tomography in breast cancer staging?

Hodgson NC, Gulenchyn KY.

J Clin Oncol. 2008 Feb 10;26(5):712-20. doi: 10.1200/JCO.2007.13.8412. Review.

PMID:
18258978
18.

F-18 FDG PET/CT demonstration of thymoma followed by development of lung cancer.

Choi JJ, Ahn MI, Park MY, Jeon JS, Park YH.

Clin Nucl Med. 2008 Mar;33(3):234-5. doi: 10.1097/RLU.0b013e31815969e7.

PMID:
18287859
19.

Diffuse intense 18F-FDG uptake at PET in unilateral breast related to breastfeeding practice.

Ko KH, Jung HK, Jeon TJ.

Korean J Radiol. 2013 May-Jun;14(3):400-2. doi: 10.3348/kjr.2013.14.3.400. Epub 2013 May 2.

20.

[FDG-PET (positron emission tomography) in the detection of primary breast cancer and lymph node involvement].

Koga S, Nakano S, Honma Y, Ogasawara N.

Nihon Rinsho. 2007 Jun 28;65 Suppl 6:379-84. Japanese. No abstract available.

PMID:
17682181

Supplemental Content

Support Center